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Inflammatory Monocytes Are a Reservoir for Merkel
Cell Polyomavirus
Kirsten D. Mertz1,2, Tobias Junt3, Mirka Schmid1, Madeleine Pfaltz1 and Werner Kempf1,4
Merkel cell polyomavirus (MCPyV) is a recently discovered virus that is implicated in the oncogenesis of Merkel
cell carcinoma (MCC). The route of dissemination and the reservoir(s) of MCPyV within the human body have
not yet been identified. In this study we describe two patients with multiple MCPyV-positive inflammatory and
neoplastic skin lesions at different anatomic sites. Patient 1 was suffering from psoriasis for many years and was
diagnosed with MCC 7 years before this study. Patient 2 had developed numerous non-melanoma skin cancer
lesions under post-transplant immunosuppression. In both patients, MCPyV DNA was detected in whole blood
and in urine using PCR and direct sequencing of PCR products. When we analyzed different blood
compartments, we found MCPyV exclusively in cell-free serum and in blood monocytes, but not in lymphocytes
or granulocytes. Upon separate analysis of resident (CD14loCD16þ ) and inflammatory (CD14þCD16)
monocytes, we detected MCPyV exclusively in inflammatory, but not in resident monocytes. Our findings
raise the possibility that MCPyV persists in inflammatory monocytes and spreads along the migration routes of
inflammatory monocytes. This points to intervention strategies to contain MCPyV. Moreover, blood or urine
tests may serve as ancillary tests to confirm MCPyV infection in a clinical setting.
Journal of Investigative Dermatology (2010) 130, 1146–1151; doi:10.1038/jid.2009.392; published online 17 December 2009
INTRODUCTION
Polyomaviruses are non-enveloped, double-stranded DNA
viruses. They often persist as latent infections in the host, but
are potentially oncogenic and may produce tumors upon
reactivation. Merkel cell polyomavirus (MCPyV) is the most
recently discovered human polyomavirus. It is monoclonally
integrated into the genome of approximately 80% of human
Merkel cell carcinomas (MCCs), which is a rare but
aggressive neuroendocrine skin neoplasia (Feng et al.,
2008). It is suspected that MCPyV has a causal role in the
oncogenesis of MCCs (Kassem et al., 2008; Viscidi and Shah,
2008; Andres et al., 2009; Duncavage et al., 2009).
The natural transmission route of MCPyV and its
reservoir(s) in the human body have not been established
yet. Other polyomaviruses, such as BK virus (BKV) and JC
virus (JCV), cause non-neoplastic inflammatory disorders of
the urinary tract, are shed through the urine, and persist in
kidney and lymphocytes (Markowitz et al., 1993; Leung
et al., 2001; Zhong et al., 2007). As a consequence, the
potential routes for BKV transmission are oral, smear
infection, blood transfusion, and organ transplantation,
particularly renal allografts (Andrews et al., 1988; Dolei
et al., 2000; Shah, 2000). For MCPyV, however, the most
common routes of interindividual transmission cannot be
appropriately addressed, until the reservoir of this virus in the
body is known. If MCPyV were able to disseminate
throughout the body through the circulation, the recipients
of blood, blood products, and solid organ transplants might
be at risk of getting exposed to this cancer-associated virus.
In this study we identified two patients with multiple skin
lesions, including MCC, non-melanoma skin cancer, actinic
keratosis, seborrheic keratosis, and psoriasis, who were tested
positive for the presence of specific MCPyV DNA sequences.
As we detected MCPyV DNA in both patients at various
anatomic locations and associated with different diseases, we
hypothesized that MCPyV might persist within and spread
through the blood. Indeed, we detected MCPyV DNA in
whole blood and in cell-free serum of both patients. Upon
analysis of the phenotype of MCPyV-positive cells in the
blood, inflammatory CD14þCD16 monocytes stood out as
the only reservoir of the virus in blood. As inflammatory
monocytes accumulate within tumors and at sites of
inflammation, our findings have important implications for
the mechanisms of systemic dissemination of MCPyV within
patients, and for the transmission between individuals.
RESULTS
Detection of MCPyV in an MCC patient
At 7 years before this study, a then 75-year-old Caucasian
female who had been chronically suffering from psoriasis was
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diagnosed with MCC. The tumor was surgically removed.
The patient received intermittent psoralen UV-A light
therapy, topical corticosteroids, and topical calcipotriol.
She was never treated with retinoids or immunomodulators.
When she presented again to our institution 7 years later, we
excised two newly arisen skin lesions—one suspicious for
seborrheic keratosis on her left thigh, and one of her psoriasis
lesions on her left upper arm. Both diagnoses were confirmed
histologically. Surprisingly, we detected MCPyV DNA in both
lesions. Consequently, we analyzed the MCC from our
archive that was excised 7 years before, together with a
tumor-free normal skin biopsy from her left forearm that was
taken at the same time. The old MCC lesion was harboring
MCPyV DNA, whereas the normal skin was negative for the
virus (Table 1).
To verify the specificity of the amplified products and to
detect the possible occurrence of genomic variants, all
MCPyV PCR products were sequenced. MCPyV sequences
from the MCC, the seborrheic keratosis, and the psoriasis
were identical. When compared with the nucleotide
sequences available in the database of the National Center
for Biotechnology Information, the identity was found to the
MCV350 genome (gb|EU375803.1 Merkel cell polyomavirus
isolate MCC350). Therefore, we concluded that the patient
had been infected with a single clone of MCPyV that had
persisted for at least 7 years in an unknown reservoir outside
the MCC before it became associated with an inflammatory
and a neoplastic skin lesion at distinct parts of the body.
As control cohorts for this isolated case, we screened
psoriasis lesions from patients chronically suffering from
psoriasis, but without MCC (n¼16, of which nine were
females, median age 46.5 years, range 18–90), and normal
skin from healthy individuals (n¼ 7, of which four were
females, median age 40, range 19–78). In none of these
control tissues, MCPyV DNA was detected using PCR.
Detection of MCPyV in a kidney transplant recipient
A 53-year-old Caucasian male recipient of a renal allograft
under long-term immunosuppression (cyclosporine,
azathioprine, and prednisolone) was regularly monitored for
skin neoplasms in our institution for several years. Over time,
he developed numerous actinic keratoses, seborrheic kera-
toses, and non-melanoma skin cancers. He harbored MCPyV
DNA in approximately 30% of his skin lesions at various
anatomic locations, e.g., in two out of three seborrheic
keratoses (Table 2). The clonality of MCPyV sequences in this
patient was confirmed by sequencing as well, and identity was
found to the MCV350 genome (gb|EU375803.1 Merkel cell
polyomavirus isolate MCC350). This, again, indicated MCPyV
persistence outside of MCCs in yet unknown reservoirs.
The presence of MCPyV DNA at different anatomic
locations in two different patients suggested that the virus
got disseminated throughout the organism by a so far
unidentified mechanism. We hypothesized that MCPyV
could spread through the blood in either free form or in
association with blood cells.
Detection of MCPyV DNA in peripheral blood and
inflammatory monocytes of both MCPyV-positive patients
On the basis of this hypothesis, we set out to test whether
MCPyV was detectable in the blood of these two patients.
Indeed, whole-blood samples of both patients were positive
for both large T and VP1 MCPyV sequences. Sequencing of
the PCR products confirmed 100% homology to the MCV350
genome in both patients. When we analyzed corpuscular
constituents of the blood and blood serum separately, we
detected MCPyV in both fractions. This showed that the virus
can occur freely or in cell-associated form. We also tested
whole-blood samples from healthy individuals (n¼7, of
which five were females, median age 43, range 25–60) and
from psoriasis patients without MCC (n¼6, of which four
were females, median age 51, range 35–81). In none of these
patients, MCPyV DNA was detected in the blood.
Next, we analyzed which blood cells carry the virus. To
this end, we first fractionated peripheral blood mononuclear
cells (PBMCs) of both patients using FACS sorting, based on
cell size (reflected as forward scatter) and granularity
(reflected as side scatter, Figure 1a). MCPyV was exclusively
associated with a population of large, non-granular cells,
whereas small non-granular cells from the lymphocyte gate
and small, granular cells from the granulocyte gate did not
contain MCPyV sequences (Figure 1b).
As the MCPyV-positive signal was detected in the
monocyte gate for both patients, we speculated that mono-
cytes were specifically associated with MCPyV. Recently,
two functional subsets of blood monocytes were character-
ized (Geissmann et al., 2003): The CD14loCD16þ ‘‘resident’’
monocytes have a longer half-life and the capacity to home to
non-inflamed tissues. These cells may be identical with the
Table 1. Results of MCPyV PCRs for patient 1
Patient 1 diagnosis Localization Year b VP1 LT-1 LT-3
MCC Forearm, left 2002 + + + +
Normal skin Forearm, left 2002 +   
Seborrheic keratosis Thigh, left 2009 + + + +
Psoriasis Upper arm, left 2009 + + + +
Abbreviations: MCC, Merkel cell carcinoma; MCPyV, Merkel cell
polyomavirus.
Table 2. Results of MCPyV PCRs for patient 2
Patient 2
diagnosis
Number of
lesions
Number of
lesions positive
for LT-3 or VP-1
Number of
lesions positive
for LT-3 and VP-1
Actinic keratosis 1 0 0
Bowen’s disease
(carcinoma in situ)
6 3 1
Seborrheic keratosis 3 2 1
Squamous cell
carcinoma
8 0 0
Abbreviation: MCPyV, Merkel cell polyomavirus.
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marginated pool of monocytes (Geissmann et al., 2008).
CD14þCD16 ‘‘inflammatory’’ monocytes, on the other
hand, have the capacity to home to inflamed tissues in
response to the chemokine (CC motif) ligand 2/monocyte
chemotactic protein-1. This dichotomy in monocyte pheno-
type and function prompted us to analyze resident and
inflammatory monocytes from the peripheral blood of patient
1 separately (Figure 2a). When we tested both, i.e., FACS-
sorted isolated HLA-DRþCD14þCD16 inflammatory
monocytes and HLA-DRþCD14loCD16þ resident mono-
cytes for MCPyV DNA, we found MCPyV to be selectively
associated with the inflammatory monocyte population
(Figure 2b). Again, sequencing confirmed the identity of the
MCPyV PCR products. Therefore, we conclude that inflam-
matory monocytes might have the unique capacity to take up
MCPyV, and carry it throughout the body.
Recruitment of inflammatory monocytes to inflamed skin
lesions in psoriasis patients
HLA-DRþCD14þCD16 inflammatory monocytes are
specifically recruited to sites of inflammation through the
chemokine receptor, chemokine (CC motif) receptor 2. We
wanted to know whether a similar mechanism operates in
psoriasis. First, we carefully analyzed defined PBMC in both
normal individuals and psoriasis patients. Specifically,
we determined the amount of resident and inflammatory
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Figure 1. Detection of Merkel cell polyomavirus (MCPyV) in blood
monocytes. (a) Whole blood of both patients was fractionated by FACS
sorting, based on cell size (forward scatter, FSC) and granularity (side scatter,
SSC). DNA was extracted from L, M, and G. (b) PCR analysis of these three
populations revealed positive MCPyV signals in only monocytes. DNA quality
was checked by b-globin PCR to determine the presence of PCR-amplifiable
DNA. The PCR products were separated on 1.5% agarose gels. DNA marker,
low-mass DNA molecular weight marker VIII (Roche; fragment lengths in
base pairs are indicated); G, granulocyte; L, lymphocyte; M, monocyte;
N, negative (H2O) control; þ , MCPyV-positive MCC control.
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Figure 2. Detection of MCPyV DNA in purified leukocyte subsets.
(a) Isolation of HLA-DRþCD14þCD16 inflammatory monocytes and HLA-
DRþCD14loCD16þ resident monocytes from peripheral blood mononuclear
cells (PBMCs) using FACS sorting. The HLA-DRþ PBMCs were determined,
and the two monocyte populations (CD14þCD16 and CD14loCD16þ ) were
isolated. Percentages of fractionated cell populations are given. (b) Detection
of Merkel cell polyomavirus (MCPyV) DNA in patient 1. Genomic DNA from
cell-free serum, whole blood, isolated blood cells, and various skin tumors of
patient 1 was amplified with primers specific for the LT1, LT3, or VP1 genes of
MCPyV. The specific LT1 amplification product is 439 bp in size. The
prominent band at about 1,000 bp observed with the LT1 primer pair
corresponds to an unspecific amplification product due to cross-reactivity
with a sequence on human chromosome 6. DNA isolated from: 1, cell-free
serum; 3, PBMCs; 5, lymphocytes; 7, monocytes; 9, CD14þCD16 mono-
cytes; 11, CD14loCD16þ monocytes; 13, urine of patient 1. DNA isolated
from: 2, cell-free serum; 4, PBMCs; 6, lymphocytes; 8, monocytes; 10,
CD14þCD16 monocytes; 12, CD14loCD16þ monocytes; 14, urine of
control individual. M, low-mass DNA molecular weight marker VIII (Roche;
fragment lengths in base pairs are indicated); N, normal skin; þ , MCC-
positive control.
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monocytes in the blood of healthy individuals and of psoriasis
patients. For FACS analysis, PBMCs of three healthy
individuals and five psoriasis patients were used. The
psoriasis patients had significantly more inflammatory mono-
cytes in the blood when compared with normal healthy
controls (P¼0.04, Mann–Whitney test; Supplementary Figure
S1 online).
Next, we asked whether monocytes might get recruited to
psoriatic skin lesions through chemokine (CC motif) receptor
2. Indeed, we observed elevated expression of the chemokine
(CC motif) receptor 2 ligand monocyte chemotactic protein-
1/chemokine (CC motif) ligand 2 in psoriatic skin, suggesting
that inflammatory monocytes may use this chemoattractant
pathway for recruitment (Ginhoux et al., 2006; Supplemen-
tary Figure S2 online). Inflammatory monocytes can differ-
entiate to macrophages at sites of inflammation (Ginhoux
et al., 2006). Therefore, we analyzed the inflammatory skin
infiltrate in psoriasis patients by immunohistochemistry using
CD68 for macrophages. In psoriatic skin, we observed
significantly more macrophages when compared with normal
skin samples (mean ± standard deviation, 12.48 ± 3.75
CD68-positive cells per high-power field in psoriatic skin vs
4.29 ± 1.95 CD68-positive cells per high-power field;
P¼0.0007, Mann–Whitney test; Supplementary Figure S2
online).
Taken together, this is correlative evidence for the fact that
inflammatory monocytes may reach psoriatic lesions through
chemokine (CC motif) receptor 2 and differentiate to
macrophages in situ. During this process, MCPyV-positive
inflammatory monocytes may import the virus into the
inflamed skin lesions.
Detection of MCPyV DNA in the urine of both patients
Other members of the polyomavirus family, e.g., BKV and JCV,
can persist in the urinary tract and can be transmitted through
the urine (Markowitz et al., 1993). This prompted us to test the
urine of both described patients, and we found it to be positive
for MCPyV DNA (Figure 2b). MCPyV was not detected in the
urine of normal healthy individuals (n¼7, of which five were
females, median age 43, range 25–60) and of psoriasis patients
without MCC (n¼ 6, of which four were females, median age
51, range 35–81). So far, it remains unclear whether MCPyV is
able to persist in the urinary tract or whether the urinary route
represents a route of virus excretion. In addition, we cannot be
sure that this virus is still infectious or whether the PCR signal
corresponds to viral particles that have been neutralized by
antibodies or to viral fragments.
DISCUSSION
This study identifies monocytes, and more specifically,
CD14þCD16 inflammatory monocytes, as a reservoir of
MCPyV. In addition, we detected MCPyV in the urine.
Although our observation relates to isolated cases, these
findings give important hints about the tropism and mode of
transmission of MCPyV.
Polyomaviruses are widespread among humans: about
80% of all adults have antibodies to BKV, JCV, or MCPyV
(Padgett and Walker, 1973; Egli et al., 2009). It is assumed
that these viruses persist lifelong and get re-activated upon
immune alterations. BKV, JCV, and MCPyV have been
associated with tumors: BKV has been found in brain tumors
and insulinomas, and JCV seems to be associated with human
tumors of the central nervous system (Dorries, 1998). Very
recently, MCPyV has been implicated in the etiology of MCC,
a malignancy of neuroendocrine cells of the skin (Feng et al.,
2008). As the reactivation of polyomaviruses may have
detrimental consequences, particularly under regimens of
therapeutic immunomodulation, it is important to understand
the life cycle of these pathogens. It is agreed upon that the
main site of BKV and JCV persistence in healthy individuals is
the kidney (Dorries, 1998). PBMCs have been proposed as
another site of persistence, at least in immunocompromised
hosts (Azzi et al., 1996). For healthy individuals, however, it
is less clear whether BKV and JCV can persist in PBMCs.
Depending on the study, BKV and JCV sequences were found
in PBMCs of 0–90% of healthy individuals tested. This huge
variation may rather point toward events of recent infection
or viral reactivation in a subgroup of patients and not toward
persistence (Dolei et al., 2000).
In contrast to other polyomaviruses, the site of persistence
and the mode of transmission have not yet been addressed for
MCPyV. Two recent studies did not detect MCPyV in a cohort
of 40 or 45 healthy blood donors (Kassem et al., 2008;
Duncavage et al., 2009). Although this shows that MCPyV
does not seem to persist frequently in PBMCs, the infectious
history of MCPyV in this patient cohort was not taken into
account. Only 25% of healthy individuals are seropositive for
MCPyV350 (Kean et al., 2009), and it remains to be observed
whether viral persistence in blood is equally low in
seropositive versus seronegative patients.
In this study we described two patients with a known
infectious history of MCPyV-positive skin lesions. Both
patients harbored MCPyV in skin lesions at various anatomic
locations, associated with mixed inflammatory infiltrates.
This led us to identify a hematologic reservoir, more
specifically CD14þCD16 inflammatory monocytes. These
cells may take up and digest opsonized, i.e., neutralized
virus. Alternatively, inflammatory monocytes may exert an
effect as efficient pathogen shuttles throughout the body
(Drevets et al., 2004). These cells are able to enter
inflammatory sites and might act as ‘‘Trojan horses’’ releasing
their pathogenic load in situ (Supplementary Figure S3
online). One of our patients suffered from psoriasis well
before developing MCC. Psoriasis lesions express chemokine
(CC motif) ligand 2/monocyte chemotactic protein-1, a
chemokine known to selectively attract inflammatory mono-
cytes (Deleuran et al., 1996). Infected monocytes localizing
within lesions of inflammatory skin diseases, such as
psoriasis, may release MCPyV locally, infect Merkel cells,
and may induce MCC (Wollina and Mahrle, 1992). In
addition, for the immunosuppressed kidney transplant
recipient, we were able to show the presence of MCPyV in
blood monocytes. This patient suffered from multiple benign
and malignant skin neoplasms accompanied by chronic
inflammatory infiltrates. Melanoma (Graves et al., 1992),
squamous cell carcinoma (Koide et al., 2004), basal cell
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carcinoma (Welss et al., 2003), HPV-16-infected tissue
(Riethdorf et al., 1996), and potentially other skin neoplasms
also express monocyte chemotactic protein-1/chemokine (CC
motif) ligand 2, and hence the mechanism of MCPyV entry to
the skin may be similar in both patients.
The scenario of inflammatory monocytes carrying MCPyV
away from MCCs into the circulation and to other sites of the
body is less likely. Inflammatory monocytes usually extra-
vasate to inflamed skin in which they differentiate to
macrophages and Langerhans cells (Ginhoux et al., 2006).
The local inflammatory milieu induces maturation of
Langerhans cells and migration to the closest draining lymph
node (Kissenpfennig et al., 2005). In other words, inflamma-
tory monocytes have not been described to re-enter the
circulation from inflammatory sites. Therefore, it is likely that
circulating monocytes have acquired MCPyV outside inflam-
matory lesions or MCCs.
In both of our patients, we detected MCPyV DNA in cell-
free serum. The MCPyV DNA signal in serum may relate to
free DNA, MCPyV particles coupled to neutralizing anti-
bodies, or infectious virus. In the absence of a plaque-forming
in vitro assay to quantify infectious MCPyV, we could not
distinguish between these three possibilities. However, the
presence of MCPyV DNA in the urine in both patients is
compatible with the idea that MCPyV gets neutralized in the
bloodstream and is then excreted through the kidneys.
Alternatively, the kidney may potentially provide a site of
MCPyV persistence, as for other polyomaviruses.
Although our observations relate to isolated cases, these
findings raise important issues related to the mode of
transmission of MCPyV. As long as it is not fully clarified
whether monocytes constitute a previously unknown long-
term reservoir of MCPyV or a shuttle for virus transmission,
caution must be exerted when transplanting organs, or when
transfusing blood from MCPyV-positive donors.
MATERIALS AND METHODS
Patients
This study was approved by the ethics review board of the Canton
Zurich, Switzerland. Written informed consent was obtained from all
patients. The study was conducted with strict adherence to the
Declaration of Helsinki Principles.
The medical records of the patients were reviewed and the
relevant information was extracted. Formalin-fixed, paraffin-em-
bedded skin biopsies were reviewed by a board-certified pathologist
(MP) and a board-certified dermatopathologist (WK). Control lesions
of immunocompetent patients were randomly selected from our
archive. These patients had never been treated with immunosup-
pressive drugs nor did they suffer from immunodeficiencies.
DNA extraction
A total of three consecutive 10 mm paraffin sections from each tissue
sample were used for DNA extraction. After deparaffinization, all
tissues were subjected to proteinase K digestion in lysis buffer (50mM
Tris–HCl, pH 8.5, 1mM EDTA, 0.5% Tween-20) at 53 1C overnight.
DNA was purified using the QIAamp DNA mini kit (Qiagen, Hilden,
Germany) and was directly used for PCR.
We collected blood and urine from patients 1 and 2 as well as from
age- and sex-matched healthy control individuals. DNA from whole
blood, PBMCs, and sorted peripheral blood cell fractions was extracted
using the QIAamp DNA blood mini kit (Qiagen). DNA from cell-free
serum and urine was extracted using the QIAamp viral RNA kit (Qiagen).
MCPyV detection by PCR
DNA quality was confirmed using b-globin PCR (GH20 primer
50-GAAGAGCCAAGGACAGGTAC-30; PCO4 primer 50-CAACTT
CATCCACGTTCACC-30). For MCPyV DNA detection we used the
primer sets LT1, LT3, and VP1 as described (Feng et al., 2008). PCR
was performed with genomic DNA using 40 cycles for each primer
set with the FastStart Taq polymerase (Roche, Basel, Switzerland) in
a final volume of 50 ml. Genomic DNA from a MCPyV-positive and
sequence-confirmed MCC was used as a positive control; water and
normal skin instead of DNA were used as negative controls. The PCR
products were detected using ethidium bromide staining after
electrophoretic migration through 1.5% agarose gels.
Sequence analyses
Amplified MCPyV PCR products were purified before sequencing
using the High Pure PCR product purification kit (Roche). PCR
products were submitted for automated sequencing using a Roche
FLX genome sequencer (Microsynth, Balgach, Switzerland). The
resulting DNA sequences were aligned against the reference
sequences of the National Center for Biotechnology Information
Entrez Nucleotide database using the center’s Blast program
(gb|EU375803.1 Merkel cell polyomavirus isolate MCC350;
gb|EU375804.1 Merkel cell polyomavirus isolate MCC339).
Isolation of PBMCs
Peripheral blood mononuclear cells were isolated from whole-blood
samples using Ficoll (Amersham Biosciences, Piscataway, NJ)
gradient centrifugation as described (Dolei et al., 2000).
FACS sorting of PBMCs
Peripheral blood mononuclear cells were stained with Pacific blue-
conjugated anti-HLA-DR, phycoerythrin-conjugated anti-CD16, and
FITC-conjugated anti-CD14 (BD Pharmingen, San Diego, CA). The two
major human monocyte subsets, CD14þCD16 and CD14loCD16þ ,
were sorted on a BD FACS Aria (BD Pharmingen) and analyzed using
FlowJo v.7 software (Tree Star, Mountain View, CA).
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